
Title:
Prostaglandin
Text:
Group of physiologically active lipid compounds
  E1 - Alprostadil
  I2 - Prostacyclin
The prostaglandins (PG) are a group of physiologically active lipid compounds called eicosanoids[1] having diverse hormone-like effects in animals.  Prostaglandins have been found in almost every tissue in humans and other animals. They are derived enzymatically from the fatty acid arachidonic acid.[2] Every prostaglandin contains 20 carbon atoms, including a 5-carbon ring. They are a subclass of eicosanoids and of the prostanoid class of fatty acid derivatives.
The structural differences between prostaglandins account for their different biological activities. A given prostaglandin may have different and even opposite effects in different tissues in some cases. The ability of the same prostaglandin to stimulate a reaction in one tissue and inhibit the same reaction in another tissue is determined by the type of receptor to which the prostaglandin binds. They act as autocrine or paracrine factors with their target cells present in the immediate vicinity of the site of their secretion. Prostaglandins differ from endocrine hormones in that they are not produced at a specific site but in many places throughout the human body.
Prostaglandins are powerful, locally-acting vasodilators and inhibit the aggregation of blood platelets. Through their role in vasodilation, prostaglandins are also involved in inflammation. They are synthesized in the walls of blood vessels and serve the physiological function of preventing needless clot formation, as well as regulating the contraction of smooth muscle tissue.[3] Conversely, thromboxanes (produced by platelet cells) are vasoconstrictors and facilitate platelet aggregation. Their name comes from their role in clot formation (thrombosis).
Specific prostaglandins are named with a letter (which indicates the type of ring structure) followed by a number (which indicates the number of double bonds in the hydrocarbon structure). For example, prostaglandin E1 is abbreviated PGE1 or  PGE1, and prostaglandin I2 is abbreviated PGI2 or  PGI2. The number is traditionally subscripted when the context allows; but, as with many similar subscript-containing nomenclatures, the subscript is simply forgone in many database fields that can store only plain text (such as PubMed bibliographic fields), and readers are used to seeing and writing it without subscript.

Contents

1 History and name
2 Biochemistry

2.1 Biosynthesis
2.2 Release of prostaglandins from the cell

2.2.1 Cyclooxygenases
2.2.2 Prostaglandin E synthase
2.2.3 Other terminal prostaglandin synthases




3 Functions
4 Types
5 Role in pharmacology

5.1 Inhibition
5.2 Clinical uses


6 Prostaglandin stimulants
7 See also
8 References
9 External links



History and name[edit]
Systematic studies of prostaglandins began in 1930, when Kurzrock and Lieb found that human seminal fluid caused either stimulation or relaxation of strips of isolated human uterus. They noted the curious finding that uteri from patients who had gone through successful pregnancies responded to the fluid with relaxation, while uteri from sterile women responded with contraction upon addition of this seminal fluid.[4] The name prostaglandin derives from the prostate gland, chosen when prostaglandin was first isolated from seminal fluid in 1935 by the Swedish physiologist Ulf von Euler,[5] and independently by the Irish-English physiologist Maurice Walter Goldblatt (1895–1967).[6][7][8] Prostaglandins were believed to be part of the prostatic secretions, and eventually were discovered to be produced by the seminal vesicles. Later, it was shown that many other tissues secrete prostaglandins and that they perform a variety of functions. The first total syntheses of prostaglandin F2α and prostaglandin E2 were reported by E. J. Corey in 1969,[9] an achievement for which he was awarded the Japan Prize in 1989.
In 1971, it was determined that aspirin-like drugs could inhibit the synthesis of prostaglandins. The biochemists Sune K. Bergström, Bengt I. Samuelsson and John R. Vane jointly received the 1982 Nobel Prize in Physiology or Medicine for their research on prostaglandins.

Biochemistry[edit]
Biosynthesis[edit]
  Biosynthesis of eicosanoids
Prostaglandins are found in most tissues and organs. They are produced by almost all nucleated cells. They are autocrine and paracrine lipid mediators that act upon platelets, endothelium, uterine and mast cells. They are synthesized in the cell from the fatty acid arachidonic acid.[2]
Arachidonic acid is created from diacylglycerol via phospholipase-A2, then brought to either the cyclooxygenase pathway or the lipoxygenase pathway. The cyclooxygenase pathway produces thromboxane, prostacyclin and prostaglandin D, E and F. Alternatively, the lipoxygenase enzyme pathway is active in leukocytes and in macrophages and synthesizes leukotrienes.

Release of prostaglandins from the cell[edit]
Prostaglandins were originally believed to leave the cells via passive diffusion because of their high lipophilicity. The discovery of the prostaglandin transporter (PGT, SLCO2A1), which mediates the cellular uptake of prostaglandin, demonstrated that diffusion alone cannot explain the penetration of prostaglandin through the cellular membrane. The release of prostaglandin has now also been shown to be mediated by a specific transporter, namely the multidrug resistance protein 4 (MRP4, ABCC4), a member of the ATP-binding cassette transporter superfamily. Whether MRP4 is the only transporter releasing prostaglandins from the cells is still unclear.

Cyclooxygenases[edit]
Prostaglandins are produced following the sequential oxygenation of arachidonic acid, DGLA or EPA by cyclooxygenases (COX-1 and COX-2) and terminal prostaglandin synthases. The classic dogma is as follows:

COX-1 is responsible for the baseline levels of prostaglandins.
COX-2 produces prostaglandins through stimulation.
However, while COX-1 and COX-2 are both located in the blood vessels, stomach and the kidneys, prostaglandin levels are increased by COX-2 in scenarios of inflammation and growth.

Prostaglandin E synthase[edit]
Prostaglandin E2 (PGE2) — the most abundant prostaglandin[10] — is generated from the action of prostaglandin E synthases on prostaglandin H2 (prostaglandin H2, PGH2). Several prostaglandin E synthases have been identified.  To date, microsomal prostaglandin E synthase-1 emerges as a key enzyme in the formation of PGE2.

Other terminal prostaglandin synthases[edit]
Terminal prostaglandin synthases have been identified that are responsible for the formation of other prostaglandins. For example, hematopoietic and lipocalin prostaglandin D synthases (hPGDS and lPGDS) are responsible for the formation of PGD2 from PGH2. Similarly, prostacyclin (PGI2) synthase (PGIS) converts PGH2 into PGI2. A thromboxane synthase (TxAS) has also been identified. 
Prostaglandin-F synthase (PGFS) catalyzes the formation of 9α,11β-PGF2α,β from PGD2 and PGF2α from PGH2 in the presence of NADPH. This enzyme has recently been crystallized in complex with PGD2[11] and bimatoprost[12] (a synthetic analogue of PGF2α).

Functions[edit]
There are currently ten known prostaglandin receptors on various cell types. Prostaglandins ligate a sub-family of cell surface seven-transmembrane receptors, G-protein-coupled receptors. These receptors are termed DP1-2, EP1-4, FP, IP1-2, and TP, corresponding to the receptor that ligates the corresponding prostaglandin (e.g., DP1-2 receptors bind to PGD2).
The diversity of receptors means that prostaglandins act on an array of cells and have a wide variety of effects such as: 

create eicosanoids hormones
acts on thermoregulatory center of hypothalamus to produce fever
increases mating behaviors in goldfish[13]
Prostaglandins are released during menstruation, due to the destruction of the endometrial cells, and the resultant release of their contents.[14][needs update] Release of prostaglandins and other inflammatory mediators in the uterus cause the uterus to contract. These substances are thought to be a major factor in primary dysmenorrhea.[15][16][17]
Types[edit]
The following is a comparison of different types of prostaglandin, including prostaglandin I2 (prostacyclin; PGI2), prostaglandin D2 (PGD2), prostaglandin E2 (PGE2), and prostaglandin F2α (PGF2α).[18]




Type

Receptor

Receptor type

Function


PGI2

IP

Gs


vasodilation
inhibit platelet aggregation
bronchodilation


PGD2

PTGDR (DP1) and CRTH2 (DP2)

GPCR


produced by mast cells; recruits Th2 cells, eosinophils, and basophils
In mammalian organs, large amounts of PGD2 are found only in the brain and in mast cells
Critical to development of allergic diseases such as asthma


PGE2

EP1

Gq


bronchoconstriction
GI tract smooth muscle contraction


EP2

Gs


bronchodilation
GI tract smooth muscle relaxation
vasodilation


EP3

Gi


↓ gastric acid secretion
↑ gastric mucus secretion
uterus contraction (when pregnant)
GI tract smooth muscle contraction
lipolysis inhibition
↑ autonomic neurotransmitters[19]
↑ platelet response to their agonists[20] and ↑ atherothrombosis in vivo[21]


Unspecified




hyperalgesia[19]
pyrogenic


PGF2α

FP

Gq


uterus contraction
bronchoconstriction
urinary bladder contractions[22]
vasoconstriction in cerebral circulation[23]

Role in pharmacology[edit]
Inhibition[edit]
.mw-parser-output .hatnote{font-style:italic}.mw-parser-output div.hatnote{padding-left:1.6em;margin-bottom:0.5em}.mw-parser-output .hatnote i{font-style:normal}.mw-parser-output .hatnote+link+.hatnote{margin-top:-0.5em}See also: Prostaglandin antagonist and Mechanism of action of aspirin
Examples of prostaglandin antagonists are:

NSAIDs (inhibit cyclooxygenase) and COX-2 selective inhibitors or coxibs
Corticosteroids (inhibit phospholipase A2 production)
Cyclopentenone prostaglandins may play a role in inhibiting inflammation
Clinical uses[edit]
Synthetic prostaglandins are used:

To induce childbirth (parturition) or abortion (PGE2 or PGF2, with or without mifepristone, a progesterone antagonist)
Induction of labour[24]
To prevent closure of ductus arteriosus in newborns with particular cyanotic heart defects (PGE1)
As a vasodilator in severe Raynaud syndrome or ischemia of a limb
In pulmonary hypertension
In treatment of glaucoma (as in bimatoprost ophthalmic solution, a synthetic prostamide analog with ocular hypotensive activity) (PGF2α)
To treat erectile dysfunction or in penile rehabilitation following surgery (PGE1 as alprostadil).[25]
To measure erect penis size in a clinical environment[26]
To treat egg binding in small birds[27]
Prostaglandin stimulants[edit]
Cold exposure and IUDs may increase prostaglandin production.[28]

See also[edit]
Prostamides, a chemically related class of physiologically active substances
References[edit]
.mw-parser-output .reflist{font-size:90%;margin-bottom:0.5em;list-style-type:decimal}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}

^ .mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:linear-gradient(transparent,transparent),url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:#d33}.mw-parser-output .cs1-visible-error{color:#d33}.mw-parser-output .cs1-maint{display:none;color:#3a3;margin-left:0.3em}.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}"Eicosanoid Synthesis and Metabolism: Prostaglandins, Thromboxanes, Leukotrienes, Lipoxins". themedicalbiochemistrypage.org. Retrieved 2018-09-21.

^ a b Ricciotti E, FitzGerald GA (May 2011). "Prostaglandins and inflammation". Arteriosclerosis, Thrombosis, and Vascular Biology. 31 (5): 986–1000. doi:10.1161/ATVBAHA.110.207449. PMC 3081099. PMID 21508345.

^ Nelson RF (2005). An introduction to behavioral endocrinology (3rd ed.). Sunderland, Mass: Sinauer Associates. p. 100. ISBN 0-87893-617-3.

^ Kurzrock, Raphael; Lieb, Charles C. (1930). "Biochemical Studies of Human Semen. II. The Action of Semen on the Human Uterus". Proceedings of the Society for Experimental Biology and Medicine. 28 (3): 268. doi:10.3181/00379727-28-5265. S2CID 85374636.

^ Von Euler US (1935). "Über die spezifische blutdrucksenkende Substanz des menschlichen Prostata- und Samenblasensekrets" [On the specific blood-pressure-reducing substance of human prostate and seminal vesicle secretions]. Wiener Klinische Wochenschrift. 14 (33): 1182–1183. doi:10.1007/BF01778029. S2CID 38622866.

^ Goldblatt MW (May 1935). "Properties of human seminal plasma". The Journal of Physiology. 84 (2): 208–18. doi:10.1113/jphysiol.1935.sp003269. PMC 1394818. PMID 16994667.

^ Rubinstein, William D.; Jolles, Michael A.; Rubinstein, Hillary L., eds. (2011). "Goldblatt, Maurice Walter". The Palgrave Dictionary of Anglo-Jewish History. Basingstoke, England: Palgrave Macmillan. p. 333. ISBN 9780230304666.

^ R.S.F.S. (3 June 1967). "Obituary Notices: M. W. Goldblatt". British Medical Journal. 2 (5552): 644. doi:10.1136/bmj.2.5552.644. S2CID 220151673.

^ Nicolaou KC, Sorensen EJ (1996). Classics in Total Synthesis. Weinheim, Germany: VCH. p. 65. ISBN 3-527-29284-5.

^ Ke J, Yang Y, Che Q, Jiang F, Wang H, Chen Z, Zhu M, Tong H, Zhang H, Yan X, Wang X, Wang F, Liu Y, Dai C, Wan X (September 2016). "Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer". Tumour Biology. 37 (9): 12203–12211. doi:10.1007/s13277-016-5087-x. PMC 5080328. PMID 27230680. Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body

^ Komoto J, Yamada T, Watanabe K, Takusagawa F (March 2004). "Crystal structure of human prostaglandin F synthase (AKR1C3)". Biochemistry. 43 (8): 2188–98. doi:10.1021/bi036046x. PMID 14979715.

^ Komoto J, Yamada T, Watanabe K, Woodward DF, Takusagawa F (February 2006). "Prostaglandin F2alpha formation from prostaglandin H2 by prostaglandin F synthase (PGFS): crystal structure of PGFS containing bimatoprost". Biochemistry. 45 (7): 1987–96. doi:10.1021/bi051861t. PMID 16475787.

^ "Hormonal and pheromonal control of spawning in goldfish (PDF Download Available)". ResearchGate. Retrieved 2017-02-04.

^ Lethaby A, Duckitt K, Farquhar C (January 2013). "Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews (1): CD000400. doi:10.1002/14651858.CD000400.pub3. PMID 23440779.

^ Wright, Jason and Solange Wyatt. The Washington Manual Obstetrics and Gynecology Survival Guide. Lippincott Williams & Wilkins, 2003. ISBN 0-7817-4363-X[page needed]

^ Harel Z (December 2006). "Dysmenorrhea in adolescents and young adults: etiology and management". Journal of Pediatric and Adolescent Gynecology. 19 (6): 363–71. doi:10.1016/j.jpag.2006.09.001. PMID 17174824.

^ Bofill Rodriguez, M; Lethaby, A; Farquhar, C (19 September 2019). "Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding". The Cochrane Database of Systematic Reviews. 9: CD000400. doi:10.1002/14651858.CD000400.pub4. PMC 6751587. PMID 31535715.

^ Moreno JJ (February 2017). "Eicosanoid receptors: Targets for the treatment of disrupted intestinal epithelial homeostasis". European Journal of Pharmacology. 796: 7–19. doi:10.1016/j.ejphar.2016.12.004. PMID 27940058. S2CID 1513449.

^ a b Rang HP (2003). Pharmacology (5th ed.). Edinburgh: Churchill Livingstone. p. 234. ISBN 0-443-07145-4.

^ Fabre JE, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH (March 2001). "Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation". The Journal of Clinical Investigation. 107 (5): 603–10. doi:10.1172/JCI10881. PMC 199422. PMID 11238561.

^ Gross S, Tilly P, Hentsch D, Vonesch JL, Fabre JE (February 2007). "Vascular wall-produced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors". The Journal of Experimental Medicine. 204 (2): 311–20. doi:10.1084/jem.20061617. PMC 2118736. PMID 17242161.

^ Stromberga, Zane; Chess-Williams, Russ; Moro, Christian (23 June 2020). "Prostaglandin E2 and F2alpha Modulate Urinary Bladder Urothelium, Lamina Propria and Detrusor Contractility via the FP Receptor". Frontiers in Physiology. 11: 705. doi:10.3389/fphys.2020.00705. PMC 7344237. PMID 32714206.

^ Joshi, Shailendra; Ornstein, Eugene; Young, William L. (2010). "Cerebral and Spinal Cord Blood Flow". Cottrell and Young's Neuroanesthesia. pp. 17–59. doi:10.1016/B978-0-323-05908-4.10007-7. ISBN 9780323059084.

^ "WHO Recommendations for Induction of Labour". NCBI Bookshelf. Retrieved 2020-07-15. Induction of labour is defined as the process of artificially stimulating the uterus to start labour (1). It is usually performed by administering oxytocin or prostaglandins to the pregnant woman or by manually rupturing the amniotic membranes.

^ Medscape Early Penile Rehabilitation Helps Reduce Later Intractable ED

^ Veale, David; Miles, Sarah; Bramley, Sally; Muir, Gordon; Hodsoll, John (2015). "Am I normal? A systematic review and construction of nomograms for flaccid and erect penis length and circumference in up to 15 521 men". BJU International. 115 (6): 978–986. doi:10.1111/bju.13010. PMID 25487360.

^ LaBonde, MS, DVM, Jerry. "Avian Reproductive and Pediatric Disorders" (PDF). Michigan Veterinary Medical Association. Archived from the original (PDF) on 2008-02-27. Retrieved 2008-01-26.{{cite web}}:  CS1 maint: multiple names: authors list (link)

^ Mary Anne Koda-Kimble (2007). Handbook of Applied Therapeutics (8th ed.). Lippincott Williams & Wilkins. p. 1104. ISBN 9780781790260.{{cite book}}:  CS1 maint: uses authors parameter (link)


External links[edit]
Prostaglandins at the US National Library of Medicine Medical Subject Headings (MeSH)
.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}vteHormonesEndocrineglandsHypothalamic-pituitaryHypothalamus
GnRH
TRH
Dopamine
CRH
GHRH
Somatostatin (GHIH)
MCH
Posterior pituitary
Oxytocin
Vasopressin
Anterior pituitary
FSH
LH
TSH
Prolactin
POMC
CLIP
ACTH
MSH
Endorphins
Lipotropin
GH
Adrenal axis
Adrenal cortex
Aldosterone
Cortisol
Cortisone
DHEA
DHEA-S
Androstenedione
Adrenal medulla
Adrenaline
Norepinephrine
Thyroid
Thyroid hormones
T3
T4
Calcitonin
Thyroid axis
Parathyroid
PTH
Gonadal axisTestis
Testosterone
AMH
Inhibin
Ovary
Estradiol
Progesterone
Activin
Inhibin
Relaxin
GnSAF
Placenta
hCG
HPL
Estrogen
Progesterone
Pancreas
Glucagon
Insulin
Amylin
Somatostatin
Pancreatic polypeptide
Pineal gland
Melatonin
N,N-Dimethyltryptamine
5-Methoxy-N,N-dimethyltryptamine
OtherThymus
Thymosins
Thymosin α1
Beta thymosins
Thymopoietin
Thymulin
Digestive systemStomach
Gastrin
Ghrelin
Duodenum
CCK
Incretins
GIP
GLP-1
Secretin
Motilin
VIP
Ileum
Enteroglucagon
Peptide YY
Liver/other
Insulin-like growth factor
IGF-1
IGF-2
Adipose tissue
Leptin
Adiponectin
Resistin
Skeleton
Osteocalcin
Kidney
Renin
EPO
Calcitriol
Prostaglandin
Heart
Natriuretic peptide
ANP
BNP

vteEicosanoidsPrecursor
Arachidonic acid
ProstanoidsProstaglandins (PG)Precursor
H2
ActiveD/J
D2
E/F
E2 (Dinoprostone)
E1 (Alprostadil)
F2α (Dinoprost):
I
I2 (Prostacyclin/Epoprostenol):
Thromboxanes (TX)
A2
B2
Leukotrienes (LT)Precursor
Arachidonic acid 5-hydroperoxide
Initial
A4
B4
SRS-A
C4
D4
E4
Eoxins (EX)Precursor
Arachidonic acid 15-hydroperoxide
Eoxins
A4
C4
D4
E4
Nonclassic
Lipoxins (LX) (A4, B4)
Virodhamine
By function
bronchoconstriction
PGD2
TXA2
LTC4
LTD4
LTE4
vasoconstriction
PGF2α
TXA2
TXB2
vasodilation
PGE2
PGI2
LTC4
LTD4
LTE4
platelets: induce
TXA2
inhibit
PGD2
PGI2
leukocytes: induce
TXA2
LTB4
inhibit
PGD2
PGE2
fever stimulation:
PGE2
labor stimulation:
PGE2 (Dinoprostone)
PGF2α (Dinoprost)

vteUterotonics/labor inducers/oxytocics (G02A)Cervical ripeningErgot alkaloids
Acetergamine
Ergometrine# (Syntometrine)
Methylergometrine
Prostaglandins and analogues
E: Misoprostol/E1#
Gemeprost/E1
Dinoprostone/E2
Sulprostone/E2
F: Dinoprost/F2α
Carboprost/F2α
Contraction induction
Oxytocin#
Carbetocin
Demoxytocin

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteDrugs for peptic ulcer and GERD/GORD (A02B)H2 antagonists ("-tidine")
Cimetidine
Famotidine
Lafutidine
Lavoltidine (loxtidine)
Niperotidine
Nizatidine
Ranitidine#‡
Roxatidine
Prostaglandins (E)/analogues ("-prost-")
Misoprostol
Enprostil
Proton-pump inhibitors ("-prazole")
Azeloprazole
Dexlansoprazole
Esomeprazole
Ilaprazole
Lansoprazole
Omeprazole#
Pantoprazole
Picoprazole
Rabeprazole
Tenatoprazole
Timoprazole
Potassium-competitive acid blockers ("-prazan")
Linaprazan
Revaprazan
Soraprazan
Vonoprazan
Others
Aceglutamide aluminum
Acetoxolone
Alginic acid
Arbaclofen placarbil
Bismuth subcitrate
Carbenoxolone
Cetraxate
Gefarnate
Lesogaberan
Pirenzepine
Proglumide
Rebamipide
Sucralfate
Sulglicotide
Telenzepine
Teprenone
Troxipide
Zinc L-carnosine
Zolimidine
Combinations
Bismuth subcitrate/metronidazole/tetracycline
Omeprazole/amoxicillin/rifabutin

See also: Helicobacter pylori eradication protocols

#WHO-EM
‡Withdrawn from market
Clinical trials:
†Phase III
§Never to phase III

vteDrugs used for glaucoma preparations and miosis (S01E)Sympathomimetics
Apraclonidine
Brimonidine (+timolol)
Clonidine
Dipivefrine
Epinephrine
Parasympathomimeticsmuscarinic
Aceclidine
Pilocarpine
muscarinic/nicotinic
Acetylcholine
Carbachol
acetylcholinesterase inhibitors
Demecarium
Ecothiopate
Stigmine (Fluostigmine
Neostigmine
Physostigmine)
Paraoxon
Carbonic anhydrase inhibitors/(sulfonamides)
Acetazolamide
Brinzolamide (+timolol, +brimonidine)
Diclofenamide
Dorzolamide (+timolol)
Methazolamide
Beta blocking agents
Befunolol
Betaxolol
Carteolol
Levobunolol
Metipranolol
Timolol
Mepindolol
Prostaglandin analogues (F2α)
Bimatoprost (+timolol)
Latanoprost (+timolol)
Tafluprost
Travoprost (+timolol)
Unoprostone
Other agents
Dapiprazole
Guanethidine
Netarsudil (+latanoprost)
Ripasudil

vteUrologicals, including antispasmodics (G04B)Acidifiers
Ammonium chloride
Calcium chloride
Urinary antispasmodics(primarily antimuscarinics)
Darifenacin
Desfesoterodine
Emepronium
Fesoterodine
Flavoxate
Imidafenacin
Meladrazine
Mirabegron
Oxybutynin
Propiverine
Solifenacin
Terodiline
Tolterodine
Trospium chloride
Vibegron
Other urologicals
Urea analogues: Acetohydroxamic acid
Salicylhydroxamic acid
Other: Collagen
Dapoxetine
Dimethyl sulfoxide
Magnesium hydroxide
Pentosan polysulfate
Phenazopyridine
Phenyl salicylate
Succinimide
Tiopronin

vteProstanoid signaling modulatorsReceptor(ligands)DP (D2)DP1
Agonists: Prostaglandin D2
Treprostinil
Antagonists: Asapiprant
Laropiprant
Vidupiprant
DP2
Agonists: Indometacin
Prostaglandin D2
Antagonists: ADC-3680
AZD-1981
Bay U3405
Fevipiprant
MK-1029
MK-7246
QAV-680
Ramatroban
Setipiprant
Timapiprant
TM30089
Vidupiprant
EP (E2)EP1
Agonists: Beraprost
Enprostil
Iloprost (ciloprost)
Latanoprost
Lubiprostone
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Sulprostone
Antagonists: AH-6809
ONO-8130
SC-19220
SC-51089
SC-51322
EP2
Agonists: Butaprost
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Treprostinil
Antagonists: AH-6809
PF-04418948
TG 4-155
EP3
Agonists: Beraprost
Carbacyclin
Cicaprost
Enprostil
Iloprost (ciloprost)
Isocarbacyclin
Latanoprost
Misoprostol
Prostaglandin D2
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
Remiprostol
Ricinoleic acid
Sulprostone
Antagonists: L-798106
EP4
Agonists: Lubiprostone
Misoprostol
Prostaglandin E1 (alprostadil)
Prostaglandin E2 (dinoprostone)
TCS-2510
Antagonists: Grapiprant
GW-627368
L-161982
ONO-AE3-208
Unsorted
Agonists: 16,16-Dimethyl Prostaglandin E2
Aganepag
Carboprost
Evatanepag
Gemeprost
Nocloprost
Omidenepag
Prostaglandin F2α (dinoprost)
Simenepag
Taprenepag
FP (F2α)
Agonists: Alfaprostol
Bimatoprost
Carboprost
Cloprostenol
Enprostil
Fluprostenol
Latanoprost
Prostaglandin D2
Prostaglandin F2α (dinoprost)
Sulotroban
Tafluprost
Travoprost
Unoprostone
IP (I2)
Agonists: ACT-333679
AFP-07
Beraprost
BMY-45778
Carbacyclin
Cicaprost
Iloprost (ciloprost)
Isocarbacyclin
MRE-269
NS-304
Prostacyclin (prostaglandin I2, epoprostenol)
Prostaglandin E1 (alprostadil)
Ralinepag
Selexipag
Taprostene
TRA-418
Treprostinil
Antagonists: RO1138452
TP (TXA2)
Agonists: Carbocyclic thromboxane A2
I-BOP
Thromboxane A2
U-46619
Vapiprost
Antagonists: 12-HETE
13-APA
AA-2414
Argatroban
Bay U3405
BMS-180,291
Daltroban
Domitroban
EP-045
GR-32191
ICI-185282
ICI-192605
Ifetroban
Imitrodast
L-655240
L-670596
Linotroban
Mipitroban
ONO-3708
ONO-11120
Picotamide
Pinane thromboxane A2
Ramatroban
Ridogrel
S-145
Samixogrel
Seratrodast
SQ-28,668
SQ-29,548
Sulotroban
Terbogrel
Terutroban
TRA-418
Unsorted
Arbaprostil
Ataprost
Ciprostene
Clinprost
Cobiprostone
Delprostenate
Deprostil
Dimoxaprost
Doxaprost
Ecraprost
Eganoprost
Enisoprost
Eptaloprost
Esuberaprost
Etiproston
Fenprostalene
Flunoprost
Froxiprost
Lanproston
Limaprost
Luprostiol
Meteneprost
Mexiprostil
Naxaprostene
Nileprost
Nocloprost
Ornoprostil
Oxoprostol
Penprostene
Pimilprost
Piriprost
Posaraprost
Prostalene
Rioprostil
Rivenprost
Rosaprostol
Spiriprostil
Tiaprost
Tilsuprost
Tiprostanide
Trimoprostil
Viprostol
Enzyme(inhibitors)COX(PTGS)
Salicylic acids: Aloxiprin
Aspirin (acetylsalicylic acid)
Benorilate (benorylate)
Carbasalate calcium
Diflusinal
Dipyrocetyl
Ethenzamide
Guacetisal
Magnesium salicylate
Mesalazine (5-aminosalicylic acid)
Methyl salicylate
Salacetamide
Salicin
Salicylamide
Salicylate (salicylic acid)
Salsalate
Sodium salicylate
Triflusal; Acetic acids: Aceclofenac
Acemetacin
Aclofenac
Amfenac
Alclofenac
Bendazac
Bromfenac
Bufexamac
Bumadizone
Cinmetacin
Clometacin
Diclofenac
Difenpiramide
Etodolac
Felbinac
Fenclofenac
Fentiazac
Glucametacin
Indometacin (indomethacin)
Indometacin farnesil
Ketorolac
Lonazolac
Mofezolac
Nabumetone
Oxametacin
Oxindanac
Proglumetacin
Sulindac
Sulindac sulfide
Tolmetin
Zidometacin
Zomepirac; Propionic acids: Alminoprofen
Benoxaprofen
Bucloxic acid (blucloxate)
Butibufen
Carprofen
Dexibuprofen
Dexindoprofen
Dexketoprofen
Fenbufen
Fenoprofen
Flunoxaprofen
Flurbiprofen
Ibuprofen
Ibuproxam
Indoprofen
Ketoprofen
Loxoprofen
Miroprofen
Naproxen
Naproxcinod
Oxaprozin
Pirprofen
Pranoprofen
Suprofen
Tarenflurbil
Tepoxalin
Tiaprofenic acid (tiaprofenate)
Vedaprofen; Anthranilic acids (fenamic acids): Etofenamic acid (etofenamate)
Floctafenic acid (floctafenate)
Flufenamic acid (flufenamate)
Meclofenamic acid (meclofenamate)
Mefenamic acid (mefenamate)
Morniflumic acid (morniflumate)
Niflumic acid (niflumate)
Talinflumic acid (talinflumate)
Tolfenamic acid (tolfenamate); Pyrazolones: Azapropazone
Dipyrone
Isopyrin
Oxyphenbutazone
Phenylbutazone; Enolic acids (oxicams): Ampiroxicam
Droxicam
Enolicam
Isoxicam
Lornoxicam
Meloxicam
Piroxicam
Tenoxicam; 4-Aminoquinolines: Antrafenine
Floctafenine
Glafenine; Quinazolines: Fluproquazone
Proquazone; Aminonicotinic acids: Clonixeril
Clonixin
Flunixin; Sulfonanilides: Flosulide
Nimesulide; Aminophenols (anilines): Acetanilide
AM-404 (N-arachidonoylaminophenol)
Bucetin
Paracetamol (acetaminophen)
Parapropamol
Phenacetin
Propacetamol; Selective COX-2 inhibitors (coxibs): Apricoxib
Celecoxib
Cimicoxib
Deracoxib
Etoricoxib
Firocoxib
Lumiracoxib
Mavacoxib
Parecoxib
Polmacoxib
Robenacoxib
Rofecoxib
Tilmacoxib
Valdecoxib; Others/unsorted: Anitrazafen
Clobuzarit
Curcumin
DuP-697
FK-3311
Flumizole
FR-122047
Glimepiride
Hyperforin
Itazigrel
L-655240
L-670596
Licofelone
Menatetrenone (vitamin K2)
NCX-466
NCX-4040
NS-398
Pamicogrel
Resveratrol
Romazarit
Rosmarinic acid
Rutecarpine
Satigrel
SC-236
SC-560
SC-58125
Tenidap
Tiflamizole
Timegadine
Trifenagrel
Tropesin
PGD2S
Retinoids
Selenium (selenium tetrachloride, sodium selenite, selenium disulfide)
PGESHQL-79PGFSBimatoprostPGI2STranylcypromineTXAS
Camonagrel
Dazmegrel
Dazoxiben
Furegrelate
Isbogrel
Midazogrel
Nafagrel
Nicogrelate
Ozagrel
Picotamide
Pirmagrel
Ridogrel
Rolafagrel
Samixogrel
Terbogrel
U63557A
Others
Precursors: Linoleic acid
γ-Linolenic acid (gamolenic acid)
Dihomo-γ-linolenic acid
Diacylglycerol
Arachidonic acid
Prostaglandin G2
Prostaglandin H2

See also
Receptor/signaling modulators
Leukotriene signaling modulators

Authority control: National libraries  
Spain
France (data)
United States
Japan






